Phase 2 Trials Begin For Promising New Dry Eye Disease Treatment From OKYO Pharma

Dr. Gary S. Jacob, CEO of OKYO Pharma OKYO, was recently a guest on Benzinga’s All Access.

OKYO Pharma is a biotechnology company focused on the treatment of ocular diseases. OKYO is currently developing OK-101 to treat dry eye disease, which is a currently underserved and untreated condition affecting millions of people in the U.S. According to the company, the addressable market exceeds $5 billion.

OK-101 has just had its First Patient First Visit, marking the beginning of its phase 2 trials. The company is very excited about this event and says it expects top line data by the end of the year.

Watch the full interview here:

Featured photo by v2osk on Unsplash.

This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice.

Market News and Data brought to you by Benzinga APIs
Posted In: BiotechPenny StocksInterviewGeneralBenzinga All AccessOKYO Pharma
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!